{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:53:23Z","timestamp":1761706403546},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1463-2","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T14:15:33Z","timestamp":1563891333000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Bogdan Marian","family":"Sorohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gener","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Andronesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Micu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Obri\u0219c\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Jurubi\u021b\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanel","family":"Sinescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u0103t\u0103lin","family":"Baston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"issue":"9569","key":"1463_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301.","journal-title":"Lancet."},{"issue":"1","key":"1463_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190430","volume":"13","author":"A Solazzo","year":"2018","unstructured":"Solazzo A, Testa F, Giovanella S, et al. The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS One. 2018;13(1):e0190430.","journal-title":"PLoS One"},{"issue":"8","key":"1463_CR3","first-page":"1356","volume":"32","author":"CJ Willey","year":"2017","unstructured":"Willey CJ, Blais JD, Hall AK, et al. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2017;32(8):1356\u201363.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"1463_CR4","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1681\/ASN.2016090938","volume":"28","author":"IA Iliuta","year":"2017","unstructured":"Iliuta IA, Kalatharan V, Wang K, et al. Polycystic kidney disease without an apparent family history. J Am Soc Nephrol. 2017;28(9):2768\u201376.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1463_CR5","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","volume":"102","author":"E Cornec-Le Gall","year":"2018","unstructured":"Cornec-Le Gall E, et al. Genkyst study group; HALT progression of polycystic kidney disease group; consortium for radiologic imaging studies of polycystic kidney disease, Harris PC. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet. 2018;102(5):832\u201344.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1463_CR6","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/j.1523-1755.2005.00201.x","volume":"67","author":"AC Ong","year":"2005","unstructured":"Ong AC, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int. 2005;67(4):1234\u201347.","journal-title":"Kidney Int"},{"key":"1463_CR7","doi-asserted-by":"crossref","unstructured":"Malekshahabi T, Khoshdel Rad N, Serra AL, et al. Autosomal dominant polycystic kidney disease: disrupted pathways and potential therapeutic interventions. J Cell Physiol. 2019;15.","DOI":"10.1002\/jcp.28094"},{"issue":"12","key":"1463_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrneph.2017.127","volume":"13","author":"MB Lanktree","year":"2017","unstructured":"Lanktree MB, Chapman AB. New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017;13(12):750\u201368.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"1463_CR9","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK)slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011;108(6):2462\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1463_CR10","doi-asserted-by":"crossref","unstructured":"Chang MY, Ma TL, Hung CC, et al. Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency. Sci Rep. 2017;7(1):7161. Published 2017 Aug 2.","DOI":"10.1038\/s41598-017-07300-x"},{"issue":"11","key":"1463_CR11","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1681\/ASN.2013111184","volume":"25","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Brosnahan G, Cadnapaphornchai MA, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014;25(11):2399\u2013418.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1463_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1681\/ASN.2017070819","volume":"29","author":"KL Nowak","year":"2018","unstructured":"Nowak KL, You Z, Gitomer B, et al. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2018;29(2):571\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1463_CR13","doi-asserted-by":"crossref","unstructured":"Hui F, Zhang Y, Ren T, et al. Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2018;3.","DOI":"10.1007\/s00228-018-2593-3"},{"issue":"1","key":"1463_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","volume":"20","author":"Y Pei","year":"2009","unstructured":"Pei Y, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"1463_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1023\/A:1008841022998","volume":"7","author":"DA Revicki","year":"1998","unstructured":"Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7:75\u201383.","journal-title":"Qual Life Res"},{"key":"1463_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","volume":"103","author":"AJ Garber","year":"1997","unstructured":"Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103:491\u20137.","journal-title":"Am J Med"},{"issue":"7421","key":"1463_CR17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bmj.327.7421.951","volume":"327","author":"JM Lord","year":"2003","unstructured":"Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327(7421):951\u20133.","journal-title":"BMJ."},{"issue":"7","key":"1463_CR18","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2215\/CJN.01870309","volume":"4","author":"M Sall\u00e9e","year":"2009","unstructured":"Sall\u00e9e M, Rafat C, Zahar JR, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4(7):1183\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1463_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","volume":"147","author":"Shari Bolen","year":"2007","unstructured":"Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007 Sep 18;147(6):386\u201399. Epub 2007 Jul 16. Review. Erratum in: Ann Intern Med. 2007 Dec 18;147(12):887.","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"1463_CR20","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.2215\/CJN.00800209","volume":"4","author":"MF Moen","year":"2009","unstructured":"Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1463_CR21","unstructured":"The EuropeanMedicines Agency (EMA). Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function: recommendations for patients with kidney impairment updated in product information [Internet], 2016.Available from \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2016\/10\/WC500214248.pdf\n                    \n                  . Accessed 5 Jan 2019."},{"key":"1463_CR22","unstructured":"The U.S. Food and Drug Administration (FDA). Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function [Internet], 2016. Available from https:\/\/ \n                    www.fda.gov\/downloads\/Drugs\/DrugSafety\/\n                    \n                   UCM494140.pdf. Accessed 5 Jan 2019."},{"key":"1463_CR23","volume":"1","author":"SR Salpeter","year":"2010","unstructured":"Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (review). Cochrane Database Syst Rev. 2010;1:CD002967.","journal-title":"Cochrane Database Syst Rev"},{"key":"1463_CR24","doi-asserted-by":"crossref","unstructured":"Ekstr\u00f6m, Nils et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ open vol. 2,4 e001076. 13 Jul. 2012.","DOI":"10.1136\/bmjopen-2012-001076"},{"issue":"10","key":"1463_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/j.1463-1326.2012.01617.x","volume":"14","author":"JK Duong","year":"2012","unstructured":"Duong JK, Roberts DM, Furlong TJ, et al. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab. 2012;14(10):963\u20135.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1463_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2337\/dc17-2231","volume":"41","author":"JD Lalau","year":"2018","unstructured":"Lalau JD, Kajbaf F, Bennis Y, et al. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018;41(3):547\u201353.","journal-title":"Diabetes Care"},{"issue":"8","key":"1463_CR27","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.2337\/dc12-1846","volume":"36","author":"A Tirosh","year":"2013","unstructured":"Tirosh A, et al. Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. Diabetes Care. 2013;36(8):2225\u201332.","journal-title":"Diabetes Care"},{"issue":"1","key":"1463_CR28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12882-018-1090-3","volume":"19","author":"A Pisani","year":"2018","unstructured":"Pisani A, Riccio E, Bruzzese D, et al. Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? BMC Nephrol. 2018;19(1):282.","journal-title":"BMC Nephrol"},{"issue":"25","key":"1463_CR29","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. TEMPO 3:4 trial Investigators.Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med"},{"issue":"20","key":"1463_CR30","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. REPRISE trial Investigators.Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930\u201342.","journal-title":"N Engl J Med"},{"issue":"9","key":"1463_CR31","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):820\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"1463_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2215\/CJN.02650313","volume":"9","author":"WE Braun","year":"2014","unstructured":"Braun WE, Schold JD, Stephany BR, et al. Low-dose rapamycin(sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin J Am Soc Nephrol. 2014;9(5):881\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1463_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/nep.12211","volume":"19","author":"TM Myint","year":"2014","unstructured":"Myint TM, Rangan GK, Webster AC. Treatments to slow progression of autosomaldominant polycystic kidney disease: systematic review and meta-analysis ofrandomized trials. Nephrology (Carlton). 2014;19(4):217\u201326.","journal-title":"Nephrology (Carlton)"},{"issue":"10","key":"1463_CR34","doi-asserted-by":"publisher","first-page":"R1198","DOI":"10.1152\/ajpregu.00262.2014","volume":"307","author":"G Jia","year":"2014","unstructured":"Jia G, Aroor AR, Martinez-Lemus LA, et al. Overnutrition, mTOR signaling, and cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol. 2014;307(10):R1198\u2013206.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6","key":"1463_CR35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.molmed.2007.04.002","volume":"13","author":"Stephen G. Dann","year":"2007","unstructured":"Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007;13(6):252\u2013259. Epub 2007 Apr 23. Review.","journal-title":"Trends in Molecular Medicine"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1463-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1463-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1463-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T23:17:56Z","timestamp":1595373476000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1463-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1463"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1463-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,23]]},"assertion":[{"value":"5 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the local ethics committee of Fundeni Clinical Institute (No.39436) and all patients signed the informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declared that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}